[ Ocugen raises $7.5M in Series B ]

Ocugen has raised $7.5 million in Series B funding.

Founded in 2013, Ocugen  is a biotechnology company focusing on developing novel biologicals targeting unmet medical needs in treating complex eye diseases.

The company will use the new financing  for the advancement of potential sight-saving ophthalmology products into clinical trials.

Funding  Series B
Founded  2013
Country  USA
City  Aurora, Colorado
Founder / CEO  Shankar Musunuri Musunuri
Deal Size  $7.5M
Investors  Abdi Ibrahim Pharmaceuticals
 Lancaster Group
 Frank Leo
 John Zhang
Previous Investors  EB5 Life Sciences